U.S. regulators approved expanded use of Roche’s drug Hemlibra to include almost all patients with hemophilia A.

Swiss drugmaker Roche is breaking into hemophilia A treatment, a $10 billion global market dominated by rivals who have cultivated close ties to sufferers of the genetic bleeding disorder.